Zydus Lifesciences Limited announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Canagliflozin Tablets, 100 mg and 300 mg, via an exchange filing.
Canagliflozin Tablet is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.
Canagliflozin Tablets had annual sales of USD 660 mn in the United States (IQVIA MAT Dec. 2022).
Defence Research Organisation Bolsters MSMEs & Startups To Make India Self-Reliant In Production
Mumbai Weather Update: Cloudy Skies, Light To Moderate Showers Expected Today; No Rain Alert Issued
GST Transition Benefit Claims From September 22 “False, Misleading & Factually Incorrect”: CBIC
International Literacy Day 2025: Know Date, Significance, Theme & More
The group now has 341 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
